Some links on this page are affiliate links: if you buy through them we may earn a commission, at no extra cost to you.
Theranos said it could collect a small blood sample, run it through a proprietary analyzer and offer many laboratory tests through a convenient retail service. That was the promise, not a proven capability: official records say the company never perfected its technology, its analyzer had accuracy and reliability problems, and conventional laboratory machines performed much of the testing.
What was Theranos trying to build?
Theranos’s pitch joined two parts of a testing process into one proposed system: a way to collect and store a small blood sample, and a compact analyzer that would run tests on it. The collection device was called a nanotainer. Official records refer to the company’s analyzers as the TSPU, Edison and miniLab. In the company’s model, a patient would provide a small sample, potentially through a finger stick, and the analyzer would produce results for tests otherwise handled by conventional laboratories.
The attraction was easy to understand. A smaller sample could make collection more convenient, while a compact analyzer could, in theory, bring testing closer to the patient and support a broader menu of results. Theranos presented this as a new way to make blood testing simpler and more accessible. But an appealing design goal is not evidence that a system can reliably do the work. The Department of Health and Human Services’ 2025 decision states plainly: “Theranos never perfected its blood testing technology.”
Recommended Free Tools
That distinction—between what the company said it was building and what its equipment could demonstrate—is essential to understanding Theranos. A nanotainer and proprietary analyzer were real parts of the company’s proposed approach. The broader claim that this approach could consistently deliver a wide range of fast, accurate tests was not established by the trial evidence summarized in official records.
Popular on Amazon
- 【90 Degree Full Function USB C Adapter】Supports the latest USB4 standard for up to 40Gbps of bandwidth, 8K video support, and up to 240W Fast charging; Support USB PD 3.1 Extended Power Range (EPR) including 140W, 180W and 240W. Your productivity is easily doubled. *Warm Tip: For the best fit, please make sure the USB-C port is fully exposed; thick or bulky cases may affect compatibility.
- 【Reliable Quality】Made from high-quality, scratch-resistant aluminum alloy, delicate metal frame. get excellent wear resistance and heat dissipation. Non-Slip Design for easier insertion and removal.
- 【Small and portable】Ultra thin size, ultra compact design, a petite physique that matches the minimalist design of your modern laptops. Coming with a slim figure that won't block the port next to the one it's plugged into.
- 【Compatibility】Widely work with most usb c, thunderbolt 4/3 devices. Compatibilit for ROG Ally, Steam Deck, Switch, MacBook Pro, Quest 3 VR headset, Surface Book 2, iPhone 18/17/16/15, Samsung Galaxy S23/S22/S21, Note 20/10, Google Pixel, ChromeBook, etc.
- 【Excellence Customer Support】If you experience any issues or cable failure, simply reach out to our dedicated customer service team. We provide a prompt response within 18 hours, providing you with the necessary technical support to resolve any concerns.
How was Theranos supposed to test blood from a finger prick?
In the proposed workflow, a small sample would be collected in a nanotainer and then analyzed using Theranos equipment. The company described a revolutionary analyzer that could use a finger-stick sample to run tests commonly performed by conventional laboratories. This was a claim about the system’s intended operation; it should not be mistaken for proof that every test could be performed that way in practice.
It helps to separate three ideas that can get blurred together. First is the sample: Theranos promoted collecting less blood than a conventional draw. Second is the instrument: the company said its proprietary analyzer would process that sample. Third is the service: Theranos sought to offer testing through a retail channel, including a relationship with Walgreens. Success at one layer would not establish success at the others. Collecting a small sample would not, by itself, show that an analyzer could perform a test accurately; a working analyzer would not, by itself, prove that a broad retail operation had been deployed as represented.
The public-facing simplicity of the pitch also concealed a demanding technical requirement. A machine must do more than produce a number: it must provide results reliable enough for the intended test. The trial evidence summarized by the Department of Justice and the Ninth Circuit concerned whether Theranos’s proprietary analyzer could deliver the accuracy, reliability, range and speed that the company represented. The records do not support treating the proposed workflow as a fully functioning, all-purpose replacement for conventional laboratory testing.
The Tool Desk
Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Did the Edison machine really run all the tests Theranos advertised?
No. The official accounts of trial evidence say the proprietary analyzer performed a limited number of tests and had problems with accuracy and reliability. Theranos also used conventional, commercially available laboratory machines for much of its patient testing, so it is inaccurate to say that every test was run on Edison—or that no patient testing ever used Theranos technology.
The Justice Department’s account of the jury evidence says the analyzer could be slower than some competing devices and, in some respects, could not compete with conventional machines. The Ninth Circuit’s 2025 opinion recounts employee testimony that Edison repeatedly failed quality-control checks and could not provide accurate results. Those points describe limitations in the proprietary system; they do not establish that every individual result from Theranos was wrong.
Also popular on Amazon
- 5-in-1 Connectivity: Equipped with a 4K HDMI port, a 5 Gbps USB-C data port, two 5 Gbps USB-A ports, and a USB C 100W PD-IN port. Note: The USB C 100W PD-IN port supports only charging and does not support data transfer devices such as headphones or speakers.
- Powerful Pass-Through Charging: Supports up to 85W pass-through charging so you can power up your laptop while you use the hub. Note: Pass-through charging requires a charger (not included). Note: To achieve full power for iPad, we recommend using a 45W wall charger.
- Transfer Files in Seconds: Move files to and from your laptop at speeds of up to 5 Gbps via the USB-C and USB-A data ports. Note: The USB C 5Gbps Data port does not support video output.
- HD Display: Connect to the HDMI port to stream or mirror content to an external monitor in resolutions of up to 4K@30Hz. Note: The USB-C ports do not support video output.
- What You Get: Anker 332 USB-C Hub (5-in-1), welcome guide, our worry-free 18-month warranty, and friendly customer service.
The distinction between Theranos’s proprietary equipment and its overall testing operation matters. A company can operate a testing service using more than one type of machine. In Theranos’s case, official trial summaries say conventional third-party devices performed much of the work. That fact does not make the proprietary analyzer’s shortcomings disappear, and it does not prove that every test was processed using conventional equipment. It means the operation was not simply the one-system model Theranos promoted.
Likewise, the names TSPU, Edison and miniLab should not be treated as interchangeable proof of a single finished product capable of every advertised test. HHS uses those names for the analyzers described in the official record, while the trial summaries focus on the limits of the proprietary analyzer and the use of third-party machines. The safe conclusion is narrow: Theranos had proprietary devices, but the evidence summarized in court records does not show that they consistently delivered the breadth and dependability promised.
What did Theranos promise, and what did the evidence show?
The gap becomes clearer when the pitch is compared with the operation along four separate dimensions: collection, test range, dependable results and the machine actually used.
| Question | Theranos’s proposed model | What official records say about the evidence |
|---|---|---|
| How was blood collected? | A small sample, with the finger-stick approach central to the pitch; the collection and storage device was called a nanotainer. | The records describe the collection concept, but that concept alone does not establish that the analyzer could produce dependable results from it. |
| How broad was the test menu? | A proprietary analyzer was presented as a way to run many tests otherwise performed by conventional laboratories. | The DOJ says the analyzer performed a limited number of tests; the records do not substantiate the full breadth of the pitch. |
| How dependable and fast was it? | The system was represented as a practical, advanced testing solution. | Trial evidence summarized by the DOJ and Ninth Circuit described accuracy and reliability problems; the DOJ also says it could be slower than some competing devices. |
| What equipment did the service use? | The public-facing idea centered on Theranos’s proprietary analyzer. | Conventional commercial machines performed much of the company’s testing, although the records do not support saying that every test used them. |
The table is not a claim that all Theranos results failed. It distinguishes a promised system from the capabilities the official trial accounts say were demonstrated. A limited test menu, recurring quality-control failures and a substantial role for conventional equipment collectively undermine the claim that the proprietary system had already replaced ordinary laboratory testing with a small-sample, one-machine solution.
Nor should “used conventional machines” be turned into an opposite oversimplification. The key question is not whether Theranos used any proprietary technology or any conventional equipment; the record says both were part of the story. The relevant question is whether the company’s own analyzer could deliver the broad, reliable performance represented to investors. The official summaries support the conclusion that it could not consistently do so.
Also popular on Amazon
- Sleek 7-in-1 USB-C Hub: Features an HDMI port, two USB-A 3.0 ports, and a USB-C data port, each providing 5Gbps transfer speeds. It also includes a USB-C PD input port for charging up to 100W and dual SD and TF card slots, all in a compact design.
- Flawless 4K@60Hz Video with HDMI: Delivers exceptional clarity and smoothness with its 4K@60Hz HDMI port, making it ideal for high-definition presentations and entertainment. (Note: Only the HDMI port supports video projection; the USB-C port is for data transfer only.)
- Double Up on Efficiency: The two USB-A 3.0 ports and a USB-C port support a fast 5Gbps data rate, significantly boosting your transfer speeds and improving productivity.
- Fast and Reliable 85W Charging: Offers high-capacity, speedy charging for laptops up to 85W, so you spend less time tethered to an outlet and more time being productive.
- What You Get: Anker USB-C Hub (7-in-1), welcome guide, 18-month warranty, and our friendly customer service.
What role did Walgreens and military claims play?
Theranos’s representations about a Walgreens rollout and military use formed part of the investor-fraud case. They should be described as claims discussed in the prosecution and appeal records, not as proof that the promised deployment had been achieved.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
The DOJ says trial evidence showed Holmes represented that Theranos technology had been deployed on a battlefield when it had not. It also says she represented that a major Walgreens expansion was expected even though the retail rollout had stalled. The Ninth Circuit’s appeal opinion discusses military work, the Walgreens relationship, device capabilities and third-party testing among the categories of investor representations considered in the case.
These were important because they connected the technical pitch to claims about real-world use and commercial reach. A product’s proposed design is one thing; claims that it has been used in a demanding setting or is poised for wide retail expansion convey a different impression about readiness. The legal record summarized here concerns what was represented to investors and the evidence presented at trial. It does not justify rewriting an expected expansion as a completed rollout, or a battlefield representation as successful deployment.
What did the court case establish about the technology?
The trial and appeal records help explain why the technology story cannot be reduced to “a machine that worked” or “a machine that never ran a test.” The jury heard evidence about the proprietary analyzer’s limitations, including accuracy and reliability problems, alongside evidence that conventional third-party machines performed much of the testing. Holmes was convicted of investor fraud, and the Ninth Circuit’s 2025 opinion addresses her appeal and recounts evidence presented at trial.
HHS’s 2025 decision also states that Holmes was convicted of wire fraud and conspiracy to commit wire fraud on investors. That finding is about investor fraud; it should not be casually translated into a claim that every Theranos patient received a wrong result, or that every test was performed on a particular machine. Official records support a more precise account: representations about device capability, testing operations, military use and Walgreens were considered in the investor-fraud case, while the proprietary testing technology itself had not been perfected.
Also popular on Amazon
- Portable and powerful USB-C HUB: BENFEI USB Type-C HUB, with super-soft and knot-free silicone woven design cable, meets most mobile office needs. Compact, lightweight, stylish, and powerful portable USB C Hub equipped with 1 x HDMI port, 1 x 100W charging, and 3 x USB ports. 18-month warranty, 24-hour response, to ensure you feel at ease when using our product.
- Design centered on comfort and reliability: Thanks to BENFEI's end-to-end in-house cable production capability, in-house PCBA and assembly capability, using the industry's most advanced silicone woven design and process, 20cm cable in length, no knots, super-soft, the HUB is easy to use in all scenarios: laptop, tablet, stand etc. Super-soft, 25000+ life cycles, to meet your daily carrying and office needs.
- 100W Charging: Support up to 90W USB C pass-through charging via Type-C port to keep your laptop powered. 10W is reserved for other interface operations. No data and video function on the Type-C port.
- 4K HDMI Display: The HDMI port supports media display at resolutions up to 4K 30Hz, keeping every incredible moment detailed and ultra vivid. Please note that the C port of the Host device needs to support video output.
- Transfer Files in Seconds: Transfer files and from your laptop at speeds up to 10 Gbps with USB A 3.2 port. Extra 2 USB A 2.0 ports are perfectly for your keyboards and mouse.
For readers trying to assess the company’s original promise, the legal record is useful because it separates marketing from evidence. It documents the claims made and describes trial evidence about actual equipment and operations. It is not a complete technical manual for every device or every test, and the evidence summarized in the cited decisions does not provide a basis here for assigning a universal error rate, a total number of affected results or a precise count of tests the analyzer could run. Those figures should not be invented to make the story sound more definitive.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Why did the Theranos pitch sound so compelling?
The idea compressed several appealing promises into one story: collect less blood, make testing more convenient, use a proprietary machine and offer results through an accessible retail channel. If all of those parts had worked together as represented, the patient-facing experience could have been meaningfully different from conventional laboratory testing. That imagined convenience helps explain the pitch’s power, but it does not answer the technical question of whether the system could produce accurate results consistently.
That is why the best explanation keeps the ambition and the evidence in view at the same time. Theranos was not merely claiming to sell a smaller container or a new brand of analyzer. It was presenting a system-level proposition: that its collection device and proprietary machines could support a broad testing service. The official evidence summarized in the case shows a gap between that proposition and the operational reality, including limited analyzer capability and extensive use of conventional machines.
For the same reason, a simple “finger-prick blood testing” label can mislead. The finger stick was part of the proposed collection method, not a guarantee that all advertised tests could be run from that sample on Theranos equipment. The crucial distinction is between the sample a company says it can collect and the validated performance of the complete testing process. In Theranos’s case, the official record says the technology was never perfected.
Free tools Windows power users keep installed
One-click scans. No signup required.
What is the most accurate short explanation of Theranos?
Theranos claimed it could use a nanotainer to collect a small blood sample and proprietary analyzers—including devices referred to as TSPU, Edison and miniLab—to run a broad range of tests. Trial evidence summarized by official sources found that the analyzer had accuracy and reliability problems, handled a limited number of tests and could be slower than some competitors; conventional commercial equipment did much of the company’s testing.
Also popular on Amazon
- 【Read before You Buy】 Note: This adapter is USB 2.0 version and cannot transmit HDM, VGA, or other video signals. Nevertheless, they are fully capable of charging devices,duplicating files, and can be seamlessly integrated with USB-C earphones, wireless network adapters, and SD card adapters.
- 【Easy to Use and Safe】Thanks to modern manufacturing techniques, we've made these adapters sufficiently compact so that they can remain inserted in your device without noticeable protrusion or inconvenience. This means you don't have to constantly plug and unplug them, reducing the likelihood of wear and misalignment, and making them more convenient to carry around.
- 【Reliable Quality】Engineered for enhanced durability, durable aluminum alloy shell material,get excellent wear resistance and heat dissipation,the male USB C and female USB connectors & the male USB and female USB C connectors are designed to be plugged and unplugged up to 20000 times. Provides data transfer, device charging, memory space expansion, and additional computer peripherals.
- 【Think more for you】Do you need to connect a USB-C-enabled device to an odd device that only has USB-A ports? Then these USB-A male to USB-C female adapters are made for you.Simply insert the adapter into the USB-A port on the device, and you can instantly connect your USB-C device to the device that originally didn't have the correct connection port.
- 【Trusted xiwxi Quality and Service】As a responsible brand seller, you will receive xiwxi's 12-month Quality assurance and lifetime friendly customer service, you're not just buying a product,you're investing in peace of mind with all-round quality and exceptional customer service.
That formulation avoids two common errors. It does not repeat the company’s pitch as though the promised system had been achieved, and it does not claim that every Theranos test was run on Edison or that every result was wrong. It reflects the narrower, better-supported conclusion in the official record: the proposed small-sample, proprietary testing model was not proven to work at the breadth and reliability represented to investors.
Frequently Asked Questions
What did Elizabeth Holmes’s investor-fraud conviction involve?
HHS describes the conviction as wire fraud and conspiracy to commit wire fraud on investors. The prosecution and appeal records discuss representations about device capabilities, Walgreens, military work and the use of third-party testing.
Does the court record say every Theranos test result was wrong?
No. The cited official summaries describe problems with the proprietary analyzer and say conventional machines performed much of the testing; they do not establish that every result was inaccurate. A claim about all results would go beyond the evidence summarized here.
Quick wins for a faster PC:
Scan for outdated or missing drivers - takes under a minuteDriver Scan →Repair Windows errors before they cause bigger problemsFix Now →What is a useful book for learning more about Theranos?
John Carreyrou’s Bad Blood: Secrets and Lies in a Silicon Valley Startup is a narrative account of Theranos and Elizabeth Holmes. The publisher lists a print edition with ISBN 9780525431992; it is further reading rather than the basis for the court-record claims in this explainer.
Say something about this film